RSV Seasonal Vaccine Introduction and Growth Strategy slide image

RSV Seasonal Vaccine Introduction and Growth Strategy

Currency 2022 currency sales exposure¹ US $ 48% Euro € 17% Japanese \ 7% Other² 28% 2023 adj. operating profit US $: 10 cents movement in the average exchange rate for full year impacts adj. operating profit by approx. +/- 8.0% Euro €: 10 cents movement in the average exchange rate for full year impacts adj. operating profit by approx. +/- 0.5% Japanese \: 10 Yen movement in the average exchange rate for full year impacts adj. operating profit by approx. +/- 1.0% 2022 2023 Historical average exchange rates quarterly Q1 Q2 Q3 Q4 Q1 Q2 US $ 1.34 1.26 1.18 1.19 1.22 1.25 Euro € 1.19 1.18 1.16 1.15 1.14 1.15 Japanese\ 156 162 161 165 162 173 Historical period end exchange rates US $ Euro € Japanese \ 1.31 1.21 1.11 1.20 1.24 1.26 1.18 1.16 1.13 1.13 1.14 1.17 160 165 160 159 165 183 GSK 1. Based on 2022 GSK continuing operations, including COVID-19 solutions 2. The other currencies that each represent more than 1% of GSK sales include Australian Dollar, Brazilian Real, Canadian Dollar, Chinese Yuan and Indian Rupee. In total, they accounted for 9% of GSK revenues in 2022. If exchange rates were to hold at the closing rates on 30 Jun 2023 ($1.26/£1, €1.17/£1 and Yen 183/£1) for the rest of 2023, the estimated impact on 2023 Sterling turnover growth for GSK would be -2% and if exchange gains or losses were recognised at the same level as in 2022, the estimated impact on 2023 Sterling Adjusted Operating Profit growth for GSK would be -5%. 55 35
View entire presentation